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The Long Noncoding RNA 
IFNG-AS1 Promotes T Helper Type 
1 Cells Response in Patients with 
Hashimoto’s Thyroiditis
Huiyong Peng1,2,*, Yingzhao Liu3,*, Jie Tian2,*, Jie Ma2, Xinyi Tang1, Ke Rui2, Xinyu Tian2, 
Chaoming Mao2, Liwei Lu4, Huaxi Xu2, Pengcheng Jiang5 & Shengjun Wang1,2
The long noncoding (lnc) RNA-Ifng-AS1 plays an essential role in the transcription of the gene 
encoding IFN-γ by Th1 cells, and its human ortholog, IFNG-AS1, is expressed in human Th1 cells. 
However, IFNG-AS1 contributing to Th1 cells’ response in Hashimoto’s thyroiditis (HT) patients 
has not been reported. Twenty-eight HT patients and 20 healthy controls were enrolled in the 
study. The proportion of circulating Th1 cells and the level of T-bet, IFNG mRNA were increased 
in HT patients, the expression of IFNG-AS1 was upregulated and positively correlated with the 
proportion of circulating Th1 cells or T-bet, and IFNG expression, or serum level of anti-thyroglobulin 
antibody/thyroperoxidase antibody in HT patients. IFNG-AS1 regulated the expression of IFNG at 
both transcriptional and translational level in human CD4+ T cells. Furthermore, strong positive 
correlations between the increased transcript level of IFNG-AS1 and the increased transcript level of 
T-bet or IFNG were revealed in thyroid tissues from HT patients. Our results indicate that enhanced 
expression of lncRNA-IFNG-AS1 contributes to Th1 cell response in HT patients and may be involved 
in the pathogenesis of HT.
Hashimoto’s thyroiditis (HT), also named chronic lymphocytic thyroiditis, is a clinical, organ-specific 
autoimmune disease characterized by lymphocytic infiltration of the thyroid parenchyma, diffusely 
enlarged thyroid gland and elevated production of autoantibodies, mainly including anti-thyroglobulin 
antibody (TgAb) and thyroperoxidase antibody (TPOAb)1,2. It is now considered to be the most common 
autoimmune disease and is often associated with other autoimmune diseases, such as Graves’ disease, 
systemic lupus erythematosus and rheumatoid arthritis3–5. HT is a complex and ever-expanding disease 
caused by genetic susceptibility, environmental factors and immunopathogenesis6. Accumulated evidence 
over recent years has suggested that CD4+ T helper cells disorder might be involved in the pathogenesis 
of HT7,8.
CD4+ T helper cells can be classified into Th1, Th2, Th17 and follicular helper T cells, based on the 
cytokine production9. The Th1 cell lineage is an inflammatory CD4+ T cells subset that mainly produces 
interferon gamma (IFN-γ ), an inflammatory cytokine that participates protectively against intracellular 
microbes, delayed type hypersensitivity and autoimmune diseases10,11. The development and differentia-
tion of Th1 cells depends on the activation of JAK/STAT pathway components STAT1 and STAT4 in the 
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presence of interleukin 1212,13. T-bet is the key transcription factor, contributing to the transcription of 
IFNG in Th1 cells14. Recent studies have shown that Th1 cells might be involved in the development of 
HT7,15,16. However, our understanding of increased Th1 cells in HT patients remains largely unknown.
Long noncoding RNAs (lncRNAs) are increasingly appreciated as key regulators of genome expres-
sion, and only some of their functions have been characterized17. In some well-studied cases, lncR-
NAs play critical roles in various biological processes and diseases18–20. However, only a few lncRNAs, 
such as lnc-DC, NRON, Gas5, have been described in the regulation of the immune system by regu-
lating particular genes21–23. Ifng-AS1 (Ifng antisense RNA 1), also named NeST (nettoie Salmonella pas 
Theiler’s), or Tmevpg1 (Theiler’s murine encephalomyelitis virus persistence candidate gene 1), a lncRNA 
was initially identified as a candidate gene for the control of Theiler’s virus persistence24. Ifng-AS1 and 
its human ortholog are located adjacent to IFN-γ -encoding gene in both mouse and human. Recent 
studies have described that Tmevpg1 (Ifng-AS1, NeST) is recognized to be a key checkpoint that requires 
T-bet for active transcription and contributes to Ifng expression in Th1 cells25,26. However, it is not yet 
known whether IFNG-AS1 regulates Th1 cells response in HT patients. Therefore, we explore the role of 
IFNG-AS1 in the pathogenesis of HT.
In this study, we investigated whether the expression of IFNG-AS1 is dysregulated in HT patients. We 
found that the expression of IFNG-AS1 was upregulated, and positively correlated with the proportion 
of circulating Th1 cells in HT patients. These findings provide new insights in understanding the role of 
IFNG-AS1 in the pathogenesis of HT.
Materials and Methods
Subjects and samples. Twenty-eight patients with HT, including twenty-three females and five 
males were enrolled into the study. The main clinical characteristics of these patients are summarized 
in Table  1. All patients were diagnosed by clinical manifestation and auxiliary examination, includ-
ing B-ultrasonic and laboratory criteria. The serum concentration of free triiodothyronine (FT3), free 
thyroxine (FT4), thyroid stimulating hormone (TSH), TgAb, and TPOAb were measured by LDX-
800 (BECKMAN COULTER, California, USA), according to the manufacturer’s instructions. Ten HT 
patients with hypothyroidism had a high level of TSH and low level of FT4, other patients with euthy-
roid had a normal level of both TSH and FT4. All patients had a positive test for TgAb and TPOAb. 
Twenty age- and sex-matched healthy subjects were included as controls. All healthy subjects were free 
of thyroid-specific autoantibodies and had no history of thyroid disease or other autoimmune diseases. 
The number of peripheral leukocytes was within normal range. Peripheral blood samples were obtained 
from all patients and healthy controls.
Fresh tissue samples from the thyroid gland of ten HT patients were collected from thyroidectomy 
and stored at − 80 °C. Lymphocytic infiltration was detected in thyroid samples. Thyroid tissues from five 
patients with simple goiter were used as control thyroid samples.
The study conformed to the principles outlined in the Declaration of Helsinki and in accordance 
with the approved guidelines. Written informed consent was obtained from each participant prior to 
blood samples collection. All samples were taken in accordance with the regulations and approval of the 
Affiliated People’s Hospital of Jiangsu University.
Cell isolation and purification. Human peripheral blood mononuclear cells (PBMCs) were isolated 
by density-gradient centrifugation over Ficoll-Hypaque solution (Haoyang Biological Technology Co., 
Tianjin, China) and stored at − 80 °C until use for quantitative real-time PCR (qRT-PCR). Human CD4+ 
T cells were purified from PBMCs by magnetic beads using CD4+ T cell Isolation Kit (Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany) according to the manufacturer’s instructions. Human CD4+ T 
cells were cultured in RPMI-1640 medium (Gibco, California, USA) supplemented with 10% fetal bovine 
serum (Gibco, California, USA) for transfection.
HT patients Healthy controls Range P-values
Number 28 20
Gender (M/F) 5/23 3/17
Age (year) 42 ± 15 42 ± 8 0.98
FT3 (pmol/liter) 4.87 ± 0.64 4.99 ± 0.56 3.1–6 0.51
FT4 (pmol/liter) 10.42 ± 2.36 10.72 ± 1.36 7.86–17.41 0.61
TSH (uIU/ml) 7.26 ± 11.26 1.98 ± 0.94 0.34–5.6 < 0.05
TgAb (IU/ml) 162.6 ± 349.9 0.3 ± 1.0 0–4 < 0.05
TPOAb (IU/ml) 570.3 ± 883.5 0.6 ± 0.5 0–9 < 0.01
Table 1. Clinical features of the HT patients and healthy controls included in the study. Data correspond 
to the arithmetic mean ± SD and were compared using unpaired t-tests. M: male; F: female.
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Thyroid mononuclear cells (TMCs) were obtained from thyroid specimens, which were minced and 
digested with collagenase II (Sigma-Aldrich, St. Louis, MO) for 1–2 h at 37 °C and then isolated by 
density-gradient centrifugation over Ficoll-Hypaque solution. Cell viability was found to be more than 
95%.
Flow cytometric analysis. Separated PBMCs were resuspended at 1 × 106/ml in RPMI-1640 medium 
containing 10% fetal bovine serum and stimulated with 50 ng/ml of phorbol myristate acetate (PMA; 
Sigma-Aldrich, California, USA) and 1 μ g/ml of ionomycin (Sigma-Aldrich, California, USA) for 2 hours 
and then incubated for an additional 4 hours in the presence of 1 μ g/ml of brefeldin-A (eBioscience, 
San Diego, USA) at 37 °C and 5% CO2. After the incubation, the suspended cells were stained with 
phycoerythrin-cyanin 5 (PE-Cy5) -conjugated anti-human CD3 mAb and fluorescein isothiocyanate 
(FITC) -conjugated anti-human CD8 mAb (eBioscience, San Diego, USA) against cell surface antigens 
for thirty minutes at 4 °C in the dark. Cells were then fixed and permeabilized using an intracellular 
staining kit (Invitrogen, Carlsbad, USA), followed by incubation for 45 minutes at 4 °C in the dark with 
PE-conjugated anti-human IFN-γ mAb (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The 
stained cells were analyzed with Accuri C6 (Becton Dickinson, San Jose, USA). To analyze the propor-
tion of Th1 cells, the population of CD3+ CD8- IFN-γ + cells was defined as Th1 cells.
RNA Isolation and Quantitative Real-Time PCR. Total RNA was isolated from PBMCs with 
TRIzol reagent (Invitrogen, California, USA) according to the manufacturer’s instructions. The cDNA was 
synthesized with random primer and ReverTraAca®qPCR RT kit (Toyobo, Osaka, Japan). Quantitative 
real-time PCR was performed in triplicate using Bio-Rad SYBR green super mix (Bio-Rad, Hercules, 
USA). Primer sequences were as follows: T-bet, sense, 5′ -TTGAGGTGAACGACGGAGAG-3′ , antisense, 
5′ -GGCATTCTGGTAGGCAGTCA-3′ ; IFNG, sense, 5′ -GAGTGTGGAGACCATCAAGGA-3′ , anti-
sense, 5′ -TGTATTGCTTTGCGTTGGAC-3′ ; IFNG-AS1, sense, 5′ -GCTGATGATGGTGGTGGCAATCT
-3′ , antisense, 5′ -TTAGCAGTTGGTGGGCTTCT-3′ . β-actin, sense, 5′ -GAGTGTGGAGACCATCAA 
GGA-3′ , antisense, 5′ -TGTATTGCTTTGCGTTGGAC-3′ . The level of each gene was expressed as the 
ratio to β-actin transcript level. Data were analyzed with Bio-Rad CFX Manager software.
Small interfering RNA knockdown. Small interfering RNA (siRNA) (Ribobio, Guangzhou, China) 
was designed against the sequence of IFNG-AS1. Nonspecific scramble siRNA was used as negative 
control (NC). The purified human CD4+ T cells were transfected with the IFNG-AS1 siRNA or NC 
at 100 nM dose using the Entranster-R (Engreen Biosystem, Co Ltd, Beijing, China) according to the 
manufacturers’ instructions for 48 hours in the presence of 0.5 μ g/ml functional anti-human CD3 mAb 
plus 2 μ g/ml functional anti-human CD28 mAb (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). 
IFN-γ + cells were measured by flow cytometric analysis.
Statistical analysis. Student’s unpaired t test was applied for two comparisons in accordance with 
the standard t test. Mann-Whitney U test was used to analyze the difference between the two groups. 
Correlation between variables was determined by Pearson’s correlation coefficient. p value < 0.05 was 
considerate as significant (*p < 0.05, **p < 0.01, ***p < 0.001). Data were analyzed with GrapPadPrism 
version 5 software (GraphPad Software, Inc., San Diego, USA).
Results
Increased circulating Th1 cells in HT patients. To quantify peripheral Th1 cells in patients with 
HT, we first gated on CD3+ CD8- cells as CD4+ T cells owing to the downregulated expression of sur-
face membrane CD4 molecule on PBMCs after being stimulated with PMA and ionomycin27 and then 
identified IFN-γ + cells to distinguish Th1 cells from activated PBMCs (Fig.  1A). The proportion of 
peripheral Th1 cells in PBMCs from patients with HT was significantly higher than that in healthy 
controls (Fig. 1B).
Subsequently, we determined the transcript level of T-bet and IFNG in PBMCs from HT patients and 
healthy controls by qRT-PCR and found that the transcript level of T-bet and IFNG were substantially 
greater in HT patients than in healthy controls (Fig. 1C,D). Moreover, a positive correlation between the 
transcript level of T-bet and the proportion of Th1 cells was found in HT patients (r = 0.4590; p = 0.0140) 
(Fig. 1E).
Positive correlations between elevated transcript level of IFNG-AS1 and increased circulating 
Th1 cells in HT patients. IFNG-AS1 is a long noncoding RNA that is comprised of four exons and 
located at Chromosome 12q15 on the opposing strand to IFNG (Fig.  2A). Ifng-AS1 (Tmevpg1, NeST) 
expression contributes to driving Th1 cell-dependent Ifng expression, and its human ortholog, IFNG-AS1 
(TMEVPG1, NEST), is selectively expressed in Th1 cells25. To address the possibility that IFNG-AS1 
contributes to increased Th1 cells in HT patients, the transcript level of IFNG-AS1 was determined by 
qRT-PCR. As shown in Fig.  2B, the transcript level of IFNG-AS1 from PBMCs was increased in HT 
patients compared with that in healthy controls. Moreover, positive correlations were observed between 
the transcript level of IFNG-AS1 and the percentage of Th1 cells (r = 0.5010; p = 0.0066) (Fig.  2C) or 
the transcript level of T-bet (r = 0.6138; p = 0.0005) (Fig. 2D) or the transcript level of IFNG (r = 0.4463; 
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p = 0.0173) in HT patients (Fig. 2E). In contrast to the relationship we observed between the transcript 
level of IFNG-AS1 and the proportion of Th1 cells, there was no correlation between the transcript level 
of IFNG-AS1 and the proportion of CD8+ IFN-γ + T cells (Supplemental Fig. 1A), which was significantly 
greater in HT patients than in healthy controls (Supplemental Fig. 1B).
Figure 1. Increased circulating Th1 cells in peripheral blood from HT patients. Peripheral blood was 
obtained from 28 HT patients and 20 healthy controls. (A) Representative flow cytometry dot plots of Th1 
cells in HT patients and healthy controls are shown. Values in the upper left rectangular region correspond 
to the proportion of Th1 cells. We used isotype control to determine the positive cells, and all of the values 
were gated on CD3+ CD8- cells. (B) The percentages of Th1 cells were compared between HT patients and 
healthy controls. (C) The transcript level of T-bet mRNA in PBMCs from HT patients and healthy controls 
was determined by qRT-PCR. (D) The transcript level of IFNG mRNA in PBMCs from HT patients and 
healthy controls was determined by qRT-PCR. (E) The correlation between the transcript level of T-bet 
mRNA and the percentage of Th1 cells in peripheral blood from 28 HT patients. Each data point represents 
an individual subject, horizontal lines show the mean. *p < 0.05; **p < 0.01.
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Influence of IFNG-AS1 on the transcription of IFNG in human CD4+ T cells. To determine 
whether IFNG-AS1 affects IFNG transcription from CD4+ T cells, human purified CD4+ T cells were 
transfected with IFNG-AS1-specific siRNA and negative control. Manipulation of IFNG-AS1-specific 
siRNA resulted in the reduction of the transcript level of IFNG-AS1 and IFNG compared with that 
of the negative control (Fig.  3A,B). Down-regulated expression of IFNG-AS1 with siRNA resulted in 
the reduction of the percentage of IFN-γ + cells compared with that of the negative control (Fig.  3C). 
Moreover, IFNG-AS1-specific siRNA suppressed the percentage of IFN-γ + cells in a dose-dependent 
manner (Fig. 3D,E). Together, these results indicate that IFNG-AS1 regulates the expression of IFNG in 
human CD4+ T cells.
Increased expression of IFNG-AS1 with elevated production of autoantibodies in HT 
patients. TgAb and TPOAb participate in thyroid destruction in the manner of antibody-dependent 
cell-mediated cytotoxicity and activation of complement. These autoantibodies are a critical diagnosis 
Figure 2. The correlation between the transcript level of IFNG-AS1 and Th1 cells in HT patients.  
(A) Genomic position of IFNG-AS1 on human chromosome. (B) The transcript level of IFNG-AS1 in 
PBMCs from 28 HT patients and 20 healthy controls was determined by qRT-PCR. (C) The correlation 
between the transcript level of IFNG-AS1 and the percentage of Th1 cells in 28 HT patients. (D) The 
correlation between the transcript level of IFNG-AS1 and the transcript level of T-bet mRNA in 28 HT 
patients. (E) The correlation between the transcript level of IFNG-AS1 and the transcript level of IFNG 
mRNA in 28 HT patients. Each data point represent an individual subject, horizontal lines show the mean. 
***p < 0.001.
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index of HT28. Our results indicated that there were positive correlations between the transcript level of 
IFNG-AS1 and the level of TgAb (r = 0.4762, p = 0.0104) or TPOAb (r = 0.3789, p = 0.0468) (Fig. 4A,B).
Upregulated expression of IFNG-AS1, T-bet and IFNG mRNA in thyroid tissues from HT 
patients. HT is an organ-specific autoimmune disease characterized by lymphoid infiltration and thy-
roid structure destruction. To determine whether IFNG-AS1, T-bet and IFNG mRNA were also expressed 
in local thyroid tissue, qRT-PCR analysis displayed enhanced expression of IFNG-AS1, T-bet and IFNG 
mRNA in TMCs from patients with HT compared to those from patients with simple goiter (Fig. 5A–C). 
Strong positive correlations were observed between the transcript level of IFNG-AS1 and T-bet mRNA 
(r = 0.8652, p = 0.0012) or IFNG mRNA (r = 0.9398, p < 0.0001) in patients with HT (Fig. 5D,E).
Discussion
Lower conservative expression of lncRNAs sequences has prevented most of the sequences from being 
functionally characterized29. Presently, more and more data suggest lncRNAs are mainly divided into 
Figure 3. Influence of IFNG-AS1 on the transcription of IFNG in vitro. Human CD4+ T cells were 
purified from PBMCs by magnetic beads and transfected with IFNG-AS1 -specific siRNA and negative 
control (100 nM) in the presence of functional anti-human CD3 mAb and anti-human CD28 mAb for 
24 h to determine the transcript level of IFNG, or 48 h before restimulation with PMA, ionomycin and 
brefeldin-A to determine the proportion of IFN-γ + cells. (A) The transcript level of IFNG-AS1 was 
determined by qRT-PCR after transfection. (B) The transcript level of IFNG mRNA was determined by 
qRT-PCR after transfection. (C) The proportion of IFN-γ + cells was analyzed by flow cytometric analysis. 
(D) The transcript level of IFNG-AS1 was detected by qRT-PCR after transfection after transfection with 
IFNG-AS1-specific siRNA in a dose-dependent manner. (E) The proportion of IFN-γ + cells was analyzed by 
flow cytometric analysis after transfection with IFNG-AS1-specific siRNA in a dose-dependent manner. The 
results are indicated as the means ± SD of three independent experiments, horizontal lines show the mean. 
*p < 0.05; **p < 0.01; ***p < 0.001.
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two functional categories that enhance or repress the transcription or translation of protein-coding 
genes. Previous studies have described T-bet may regulate the expression of Ifng via inducing active 
transcription of Ifng-AS1 (Tmevpg1, NeST), a Th1-specific lncRNA that contributes to the transcription 
of Ifng25,26. Transgenic mice models also have demonstrated that Ifng-AS1(NeST) plays a critical role in 
increasing Theiler’s virus persistence and resisting Salmonella enterica pathogenesis30. However, little is 
known regarding the role of IFNG-AS1 in the disease pathogenesis of HT. Based on this, we speculated 
that the expression of IFNG-AS1 might contribute to increased Th1 cells in HT patients. As expected, a 
Figure 4. The correlation between the transcript level of IFNG-AS1 and serum autoantibodies in HT 
patients. The correlation between the transcript level of IFNG-AS1 and serum concentrations of TgAb (A) 
and TPOAb (B) in 28 HT patients.
Figure 5. Upregulated expression of IFNG-AS1, T-bet and IFNG mRNA in thyroid tissues. The transcript 
level of IFNG-AS1 (A), T-bet mRNA (B) and IFNG mRNA (C) in thyroid glands were determined by qRT-
PCR from 10 patients with HT and 5 patients with simple goiter. Correlations between the transcript level of 
IFNG-AS1 and T-bet mRNA (D) or IFNG mRNA (E) in thyroid glands from 10 HT patients. Each data point 
represents an individual subject, horizontal lines show the mean. *p < 0.05; **p < 0.01.
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higher transcript level of IFNG-AS1 was found in peripheral blood and thyroid tissues from HT patients. 
Furthermore, positive correlations were found between the transcript level of IFNG-AS1 and the pro-
portion of Th1 cells, as well as transcript level of T-bet or IFNG in HT patients. Although a study has 
reported that Tmevpg1 promoted the transcription of Ifng from murine Th1 cells in vitro25, the influence 
of IFNG-AS1 on IFNG transcription in humans is still unknown. To investigate the role of IFNG-AS1 
in human CD4+ T cells, we used IFNG-AS1-specific siRNA to knockdown IFNG-AS1 and observed 
the alteration of IFNG. IFNG-AS1 knockdown resulted in a considerable reduction of IFNG in gene 
expression and protein expression (IFN-γ ). Interestingly, IFNG-AS1-specific siRNA downregulated the 
proportion of CD4+ IFN-γ + cells in a dose-dependent manner. In the present study, we provide direct 
evidence that IFNG-AS1 regulates the transcription of IFNG from human Th1 cells in vitro. However, the 
epigenetic mechanism of Ifng-AS1 promotes Ifng expression in Th1 cells is poorly understood.
The expression of Tmevpg1 was found in Th1 cells from both mice and human, but was not detected 
in effector CD8+ T cells under the same culture conditions, which also produced IFN-γ 25. Our supple-
mental data also demonstrated that there was no correlation between the transcript level of IFNG-AS1 
and increased proportion of CD8+ IFN-γ + T cells in HT patients. One possible interpretation is the 
different mechanisms of IFN-γ production between Th1 cells and CD8+ T cells. T-bet is the master 
regulator of Ifng expression in Th1 cells14. However, IFN-γ production by effector CD8+ T cells is 
dependent of Eomesodermin (Eomes), a paralogue of T-bet, which plays key role in the differentiation 
and function of CD8+ T cells31. Another possible interpretation is the difference in regulating IFNG 
expression by IFNG-AS1 between Th1 cells and CD8+ T cells. Although one model is generally indi-
cated that Ifng-AS1(NeST) was required for Ifng expression in response to infection with Salmonella, and 
Ifng-AS1(NeST) was found to bind WDR5 component of histone H3 lysine 4 methytransferase complex, 
and to modify H3K4me3 at the Ifng locus by CD8+ T cells30. The differences between these reported find-
ings may be due to different animal models, and the further mechanisms will be investigated in future.
Accumulating studies have demonstrated that HT is a Th1-mediated autoimmune disease because 
there are abundant Th1 cells infiltrating and thyrocyte destruction in HT patients14,31,32. Our results 
also showed that the proportion of Th1 cells and related genes, such as T-bet and IFNG, were higher in 
peripheral blood and thyroid gland from HT patients. It is widely accepted that elevated serum concen-
trations of TgAb and TPOAb are the most common manifestations of HT. These autoantibodies could 
indicate the development of HT, and IFN-γ production by Th1 cells drives the generation of autoantibod-
ies28. We analyzed the correlation between the transcript level of Ifng-AS1 and serum level of autoanti-
bodies. Positive correlations were found between the transcript level of Ifng-AS1 and the level of TgAb or 
TPOAb. These data suggest that IFNG-AS1 expression could reflect disease severity of HT to some extent.
In summary, our results demonstrate that the lncRNA IFNG-AS1 is significantly increased and may 
contribute to the pathogenic role of Th1 cells response in HT patients. Further exploration of the mecha-
nism of IFNG-AS1-driven Th1 cells response may lead to better understanding of the pathogenesis of HT.
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